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Abstract 
Antimicrobial peptide has the potential to be developed as new kind of antimicrobial agents with novel action mech-
anism. However, the susceptibility to protease is a drawback for potential peptides to be clinical used. d-amino acid 
substitution can be one way to increase the proteolytic stability of peptides. In the present study, we synthesized the 
d-lysines substituted analog (d-lys-MPI) and the d-enantiomer of polybia-MPI (D-MPI) to improve the proteolytic resist-
ance of polybia-MPI. Our results showed that, the stability of its d-amino acid partially substituted analog d-lys-MPI was 
increased. However, it lost antimicrobial activity at the tested concentration with the loss of α-helix content. As shown 
in the CD spectra, after substitution, the spectra of D-MPI is symmetrical to MPI, indicated it turned into left hand 
α-helical conformation. Excitingly, the stability of D-MPI toward the tested protease was improved greatly. Notably, the 
antimicrobial activity of D-MPI was comparable to its L-counterpart MPI, even improved. In addition, the hemolytic 
activity of D-MPI was lowered. This also indicated that the action target of antimicrobial peptide polybia-MPI was not 
chiral specific. So, D-MPI may offer a therapeutic strategy to defend the infection of microbes, considering its stability 
to protease and relatively lower cytotoxicity to human erythrocytes.
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Introduction
Antimicrobial peptide (AMPs) is a component of innate 
defense system in most multicellular organisms, from 
humans to plants to insects. To date more than 2200 nat-
ural or synthetic AMPs have been reported through the 
antimicrobial peptide database (APD) (Silva et al. 2014). 
Antimicrobial peptides (AMPs) are generally composed 
of short sequences of 10–100 amino acids residues and 
highly amphipathic and membrane active (Reddy et  al. 
2004). AMPs have a broad spectrum of antibacterial, 
antifungal, antiviral, and anti-tumor activity at low con-
centrations. Unlike traditional antibiotics, antimicrobial 
peptides can regulate the host immune system and kill 
bacteria directly (Gottler and Ramamoorthy 2009). Fur-
thermore, other biological activities of AMPs have also 
been described as following: neutralization of endotox-
ins, immune-modulating properties, chemokine-like 
activities, and induction of both angiogenesis and wound 
repair (Guaní-Guerra et al. 2010).
Although AMPs have broad spectrum of antimicrobial 
activity, the therapeutic applications of them still have 
many limitations, such as cytotoxicity, instability and 
high cost. Many antimicrobial peptides have cytotoxic-
ity to mammalian cells at high concentrations, which may 
be due to membrane cracking mechanism (Marr et  al. 
2006). Moreover, AMPs could be degraded or removed 
by the endogenous protease or secreted by organism 
before arriving at the action sites. Therefore, their anti-
microbial activities were greatly reduced or completely 
lost (Bowdish et al. 2005; Maisetta et al. 2008). The first 
commercial AMP was pexiganan acetate (MSI-78) which 
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was an α-helical magainin variant peptide. MSI-78 has 
broad spectrum activity for treating foot ulcers and has 
developed into phase III clinical trials (Kang et al. 2012). 
BPI is a cationic protein from human neutrophil-derives 
which has antibacterial activity has just entered phase-III 
clinical trials (Ge et al. 1999; Hancock and Lehrer 1998). 
And up to now, no one have obtained US Food and Drug 
Administration (FDA) approval, except gramicidin for 
topical administrations (Steckbeck et al. 2014).
Recently, in order to reducing the toxicity and proteo-
lytic degradation, many strategies were developed. It has 
been reported that the toxicity of AMPs can be reduced 
by modest sequence modifications (Kim et  al. 2014). 
Strategies used to protect AMPs from protease degrada-
tion were mainly including cyclization, incorporation of 
non-proteinogenic amino acids, and sequence modifica-
tion such as d-amino acids to replace the l-amino acids 
(Braunstein et al. 2004; Choi et al. 2013; Hamamoto et al. 
2002; Lee and Lee 2008). Furthermore, several studies 
had reported d-amino acid substitution can improve the 
activity of AMPs or retain its activity, and more impor-
tantly can improve their stability.
Polybia-MPI, was a cationic peptide originally iso-
lated from the venom of the social wasp Polybia paulista 
(Souza et  al. 2005). Its primary sequence is IDWKKLL-
DAAKQIL-NH2 (1654.09  Da). We have demonstrated 
that Polybia-MPI displays potent antibacterial activity 
against both Gram-positive and Gram-negative bacte-
ria. Furthermore, it was also found that polybia-MPI has 
potent antifungal activity and antitumor activity, and low 
toxicity to human red blood cells and normal fibroblasts 
(Wang et al. 2008, 2013). However, it is susceptive to the 
protease, which limits its clinical application. In the pre-
sent study, its partial d-amino acid derivative d-lys-MPI 
(in which all l-lys was substituted by d-lys) and d-enan-
tiomer (D-MPI) were synthesized by solid-phase peptide 
synthesis. Then their antimicrobial activity, hemolytic 
activity and stability were determined. Furthermore, the 
effect of such modification on the bioactivity, secondary 




(1654.09  Da) and its analogues were synthesized by the 
standard Fmoc solid-phase peptide synthesis (Fields and 
Noble 1990; Wang et al. 2008). Each of synthesized pep-
tide was purified to over 95% by reversed-phase high 
performance liquid chromatography (RP-HPLC) using a 
μ Bondapak C18 19- by 300-mm column. The flow rate 
was 8  ml/min and the gradient used was 5–95% sol-
vent (CH3CN/H2O with 0.1% trifluoroacetic acid) over 
60  min (Yan et  al. 2012). The molecular weights were 
verified by matrix-assisted laser desorption ionization-
time-of-flight mass spectrometry (ESI–MS). All the pep-
tides were dissolved in deionized water and diluted by 
PBS before use.
Antimicrobial assays
The minimal inhibitory concentration (MIC) of the pep-
tides was measured in triplicate by the standard broth 
microdilution method (Peterson et al. 1980; Wang et al. 
2012). In brief, bacteria/fungi were cultured overnight to 
mid-logarithmic-phase in Mueller–Hinton broth (MHB)/
Sabouraud dextrose broth. The cultures were diluted to 
a final concentration of 2 × 104 cfu/ml in fresh Mueller–
Hinton broth (MHB)/Sabouraud dextrose broth. Each 
well of 96-well propylene microtitre plates was filled with 
100 µl cell suspension and 100 μl peptide solution of two-
fold diluted serially. And the final concentrations of pep-
tide mixtures ranged from 1 to 256  µM. Controls were 
done without peptides. After 18 h of incubation at 37 °C 
(bacteria)/35  °C (fungi), the minimal inhibitory concen-
tration (MIC) of the peptides was evaluated by visible 
turbidity in each well.
The minimal bactericidal concentrations (MBCs) and 
minimum fungicidal concentration (MFCs) of the pep-
tides was determined at the end of the incubation period 
by transferring 50 µl aliquots onto agar plates and incu-
bated overnight at 37  °C/35  °C. The MBC/MFC was set 
as the lowest concentration of the number of CFUs that 
reduced at least 99.9%.
Time‑kill analysis
Strains was grown overnight with shaking to mid-loga-
rithmic phases described above (Wang et  al. 2015). The 
cultures containing 104–105 CFU/ml was incubated with 
different concentration of peptides which determined by 
MIC assay via the broth microdilution method. A no-
peptide (control) tube was also included in each run. The 
cultures were incubated in a 37  °C/35  °C. shaking incu-
bator. At different time intervals over the incubation 
period, samples from each tube were removed respec-
tively and serially (tenfold) diluted, and 100 µl of the dilu-
tion were plated on agar plates. Plates were incubated 
at 37 °C/35 °C and determine the numbers of CFU after 
24 h.
Hemolytic activity
Fresh human blood was collected in heparinized-tube, 
diluted in cold PBS (pH 7.4) and centrifuged at 800g for 
10 min to remove the serum and buffy coat. The eryth-
rocytes were washed twice time and re-suspended in the 
same buffer to a final erythrocyte concentration of 8% for 
the hemolysis assay (Sharma and Sharma 2001). The RBC 
(red blood cell) suspension of 100 µl was transferred into 
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a 96 well microtiter plate. Peptides were dissolved in PBS 
(pH 7.4) of different concentrations from 2 to 256  µM 
were incubated with 8% erythrocytes suspension for 
60 min at 37 °C. Subsequently, the plate was centrifuged 
at 1200×g for 10  min. Then, aliquots of 100  µl super-
natant were retransferred to an another 96-well plates 
and measured to monitor the release of hemoglobin by 
microplate reader (Bio-Rad 680) at 490 nm, which indi-
cated RBC membrane damage. 100  µl RBC (red blood 
cell) suspension with 0.2% Triton-X 100 or PBS was used 
as positive and negative control, respectively. Hemolysis 
rate was determined as below:
where A is the absorbance of indicator mixtures with dif-
ferent factors, A1 and A2 are the positive control, and the 
negative control, respectively (Kim et al. 2011).
Circular dichroism spectroscopy analysis
The circular dichroism (CD) spectra of peptides were 
measured on an Olis DSM 1000 CD spectrophotometer 
(USA) in spectra between 195 and 240 nm under nitro-
gen flush in 1 mm path length at room temperature. The 
scanning speed was 100 nm/min, 2 s response time and 
1.0  nm spectral band width. The measurements were 
performed with a peptide concentration of 50 mM. The 
spectra were measured in 50% TFE (v/v) and 10 mM PBS 
(pH 7.4), and the average of four scans was taken.
Assessment of stability
Viability assay
Viability assay different concentration of trypsin (from 
0.0002 to 2 mg/ml) incubated with peptides for 1 or 6 h 
at 37  °C, and the enzymatic activity was terminated by 
additional heat inactivation at 60 °C for 20 min. Then the 
trypsin treated peptides were incubated with Escheri-
chia coli (ATCC25922) at the concentration of MIC in 
96-wells microtiter plate overnight at 37  °C (Choi et  al. 
2013). The growth inhibitory effect was determined 
by measuring the absorbance at 600  nm. Then we took 
100 μl samples of 6 h from each well with the concentra-
tion of 0.2  mg/ml and plated onto MH broth ager after 
dilution. After overnight incubation at 37  °C, photos of 
plates were photographed and the colonies on the plate 
were counted.
Radial diffusion assay
The enzymatic stability of Polybia-MPI and its analogues 
was evaluated by a modification of the sensitive radial dif-
fusion assay. The bacteria were cultured until the optical 
density at 600 nm (OD600) of an aliquot reached 0.5. One 
milliliter of the bacteria suspension was added to 100 ml of 
Hemolysis rate(%)
= (A− A2)/(A1− A2)× 100%
previously autoclaved, warm Mueller–Hinton agar (MHA)/
Sabouraud dextrose agar. The medium were poured into 
layer of a 5 mm deep. Wells were performed with a sterile 
plastic bore of a 3-mm-diameter gel punch. Following the 
addition of 20  µl pre-incubated mixture of peptides and 
different concentrations of trypsin or chymotrypsin for 
Table 1 MIC values of  polybia-MPI, D-MPI and  d-lys-MPI 




 E. coli (ATCC 2592) 32 16 >256
 E. coli (ML-35) (ATCC 43827) 32 32 >256
 Klebsiella influenza (ATCC 700603) 64 64 >256
 Pseudomonas aeruginosa (ATCC 
27853)
128 64 >256
 sakazakii (ATCC 29544) 64 32 >256
 Staphylococcus aureus (ATCC 29213) 32 16 >256
 Bacillus subtilis (ATCC 23857) 8 8 >256




 Candida glabrata ATCC (ATCC 2001) 8 16 128
 Candida albicans ATCC (ATCC 14053) 16 16 256
 Candida parapsilosis (ATCC 22019) 64 32 >256
 Candida tropicalis (ATCC 750) 8 16 64
 Candida krusei (ATCC 6258) 8 8 128
Table 2 MBC/MFC values of polybia-MPI, D-MPI and d-lys-




 E. coli (ATCC2592) 32 16 >256
 E. coli (ML-35) (ATCC43827) 256 64 >256
 Klebsiella influenza (ATCC 700603) 256 128 >256
 Pseudomonas aeruginosa 
(ATCC27853)
>256 128 >256
 sakazakii (ATCC 29544) 64 64 >256
 Staphylococcus aureus (ATCC29213) 128 64 >256
 Bacillus subtilis (ATCC23857) 8 8 >256




 C. glabrata (ATCC 2001) 32 32 256
 C. albicans (ATCC 14053) 16 16 >256
 C. parapsilosis (ATCC 22019) 128 32 >256
 C.tropicalis (ATCC 750) 32 16 128
 C. krusei (ATCC 6258) 16 8 256
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Fig. 1 Time-killing kinetics curves for polybia-MPI and D-MPI against E. coli (a and b), S. aureus (c and d) and C. glabrata (e and f). Standardized cells 
suspensions were incubated with a final concentration of peptides of 1/2× MIC, 1× MIC, 2× MIC, 4× MIC. At different time intervals, samples were 
taken respectively from each tube and serially diluted. Then 100 µl of the dilution were plated for colony counts. Controls were without peptide. 
Each data point represents mean result ± standard deviation (error bars)
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4 h into wells. The plates were incubated at 37 °C for 18 to 
24 h. An equal volume of 20 µl mixture had no trypsin or 
chymotrypsin was used as the control. The size of the clear 
zones surrounding each well as indicators of the enzymatic 
stability of Polybia-MPI and its analogues.
RP‑HPLC analysis
The stability of polybia-MPI and its analogues was 
assayed with trypsin or chymotrypsin in a volume ratio of 
1:15 (peptide:trypsin) (Choi et al. 2013; Hamamoto et al. 
2002; Molhoek et al. 2011). Peptides at the concentration 
of 10 mM were incubated with trypsin or chymotrypsin 
(0.2  mg/ml) at 37  °C. 40  µl samples of the incubations 
were taken for the time of 0 and 360  min, respectively. 
Then, the samples were mixed with 80  µl of 15% trif-
luoroacetic acid (TFA) and 80 µl acetonitrile which incu-
bated at 4  °C for at least 15 min to precipitate proteins. 
The supernatant was collected of each sample after cen-
trifugation at 13,000 rpm for 10 min and were detected 
with reverse phase high performance liquid chromatog-
raphy (RP-HPLC) analysis.
Confocal laser scanning microscopy
Candida glabrata cells were cultured overnight to mid-
logarithmic-phase in Sabouraud dextrose broth. After 
centrifugation and suspension, the cells were incubated 
with polybia-MPI and its analogues at final concentration 
of 5× MIC for 2 h at room temperature. Then, PI (50 µg/
ml) was added and was further incubated for 5 min in the 
dark (Wang et al. 2012).
Results
Antibacterial and bactericidal activity
The antimicrobial activity of d-lys-MPI and D-MPI 
against bacteria and fungi were determined. As shown 
in Table  1, D-MPI could potently inhibit the growth of 
all tested bacterial and fungal strains with MIC values 
almost in the range of 8–64  µM. However, d-lys-MPI 
was inactive against bacteria and much less active against 
fungal strains at the tested concentration. Compared 
with polybia-MPI, the inhibitory effects of D-MPI was 
Fig. 2 The hemolytic activity of polybia-MPI and synthetic D-MPI and 
d-lys-MPI against human erythrocytes were determined. Fresh human 
blood was collected and centrifuged to remove the serum and buffy 
coat, and re-suspended to a final erythrocyte concentration of 8% 
erythrocytes suspension. Then, peptides of different concentrations 
from 2 to 256 μM were incubated with erythrocytes suspension for 
60 min. Subsequently, the erythrocytes suspension was centrifuged 
and measured to monitor the release of hemoglobin at 490 nm
Fig. 3 Circular dichroism spectra analysis of polybia-MPI and its analogues. a sodium phosphate buffer. b Membrane-mimicking environment (50% 
TFE)
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improved more or less, which also could be seen in the 
bactericidal or fungicidal activity (Table  2). As shown 
in Fig.  1, the improvement of bactericidal or fungicidal 
activity also could be reflected in the time-killing curves 
of D-MPI against the tested strains.
Hemolytic activity
The hemolytic activity of polybia-MPI, D-lys-MPI and 
D-MPI against human erythrocytes was determined 
with the concentration ranging from 1 to 256  µM. As 
indicated in Fig. 2, no significant hemolytic activity was 
found under the concentration of 100 μM. Compared to 
its L-counterpart polybia-MPI, the hemolytic activity of 
D-MPI was decreased after the d-amino acid substitu-
tion. After substitution of l-lysine by d-lysine in the pep-
tide sequence, the hemolytic activity also was abrogated.
Circular dichroism spectroscopy analysis
The secondary structure of these peptides were deter-
mined in 10 mM sodiumphosphate buffer (PBS, pH 7.4) 
and a membrane-mimicking environment (50% 2,2,2-tri-
fluoroethanol) by circular dichroism spectroscopy. As 
shown in Fig.  3, all the peptides displayed a unordered 
structure in PBS. In the membrane-mimicking environ-
ment, D-MPI showed a negative band at 195  nm, and 
two positive bands near 208 and 222  nm, which was 
mirror symmetrical to its L-counterpart polybia-MPI. 
D-MPI takes a left hand α-helical conformation in the 
membrane-mimicking environment. However, the d-lys-
MPI showed a decreased α-helical conformation after 
the substitution of l-lysine with d-lysine for there is a 




One of the major limitation of AMPs for clinical use is 
that AMPs could be easily degraded by the endoge-
nous proteases. To test the stability of polybia-MPI and 
D-MPI, first 1 mg/l of the peptides were incubated with 
trypsin and chymotrypsin for 4 h for degradation. After 
the enzyme was heat inactivated at 60  °C for 15 min, E. 
coli was added and co-incubated for 3 h. Then, the treated 
bacteria were coated to plate and incubated at 37 °C for 
24 h. As shown in Fig. 4, there are no colony grown on 
the trypsin-D-MPI-treated plate, while there are many 
colonies grown on the trypsin-MPI-treated plate. D-MPI 
showed significant protease resistance against trypsin. To 
further examine the susceptibility of peptides to protease, 
peptides was incubated with the different concentration 
of trypsin (a and b) and chymotrypsin (c and d) (ranged 
from 0.0002 to 2 mg/ml) for 1 and 6 h respectively, then 
the relative survival rate of E. coli were determined. As 
shown in Fig. 5, trypsin and chymotrypsin could totally 
inhibit the antimicrobial activity of polybia-MPI at the 
concentration of 0.002 mg/ml after incubation 1 h, while 
D-MPI retained its antimicrobial activity after incuba-
tion with 2 mg/ml of trypsin and chymotrypsin for 6 h. 
This result was further confirmed by radical diffusion 
assay. As shown in Fig. 6, the inhibition zone diameters 
in polybia-MPI treated group were decreased even dis-
appeared after incubation with 0.02–2 mg/ml of trypsin 
and chymotrypsin, respectively. However, in the D-MPI 
treated group the inhibition zone diameters was almost 
the same as control after the incubation with 2 mg/ml of 
tested proteases.
RP‑HPLC analysis
In the present study, HPLC was used to determine 
the stability of polybia-MPI, d-lys-MPI and D-MPI to 
trypsin, chymotrypsin and proteases in human serum. 
When comparing the HPLC profile of untreated peptides 
Fig. 4 The effect of protease on the bactericidal activity of polybia-
MPI and D-MPI. Peptides were incubated with the same volume of 
PBS (Left) or trypsin (Right) at 37 °C for 4 h. The enzyme was heat 
inactivated at 60 °C for 20 min, and E. coli suspension was added 
and co-incubated for 3 h. Then, the mixtures were plated onto MH 
broth ager and incubated for 18–24 h. Pictures of each plate were 
photographed
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to the HPLC profile of trypsin and chymotrypsin treated 
peptides, it was found that polybia-MPI was susceptible 
to all the tested enzymes and serum, while its partially 
d-lysine substituted analogue and fully d-amino acid 
substituted were not or only partly degraded after treat-
ment (Fig. 7).
Peptides induced cell membrane permeabilization
To determine the effect of D-MPI on the integrity of the 
fungal cell membrane, PI uptake assay was employed in 
the present study. PI was a kind of DNA intercalating 
fluorescent dye, which could only pass through the dam-
aged cell membranes and combined with DNA to form 
a PI-DNA complex. As shown in Fig. 8, there is no fluo-
rescence in the control group (A–C), while the D-MPI 
treated group (G–I) showed fluorescence as its L-coun-
terpart treat group (D–F), indicating that D-MPI also 
could disrupt the integrity of the cell membrane.
Discussion
Since the golden age of antibiotics, antibiotics had 
truly become the “panacea” in the field of medicine and 
were being used to treat even the most common infec-
tions. However, spawned a series of multi-drug resist-
ant bacteria with the indiscriminate use and abuse of 
antibiotics,traditional antibiotics have been unable to 
meet the needs of clinical medicine (Wang et  al. 2016). 
Therefore, the urgent need for new antibiotics has stim-
ulated the rapid development of antimicrobial peptides. 
Most antimicrobial peptides are presented with a posi-
tive charge at neutral PH and have an amphiphilic topol-
ogy, so they can combined with a negatively charged 
phospholipid head, and ultimately damage membrane 
structure through interactions with cytoplasmic mem-
brane (Wang et al. 2013). Due to these special properties, 
antimicrobial peptides are therefore considered to be a 
potential alternative to traditional antibiotics. Although 
Fig. 5 Inhibition effect of protease on the antimicrobial activity of polybia-MPI and D-MPI. The proteases used were trypsin (a and b) and chymot-
rypsin (c and d). Peptides with proteases of different concentration which ranged from 0.0002 to 2 mg/ml (tenfold) were incubated for 1 h (left) or 
6 h (right) at 37 °C, respectively. Then tested for its antimicrobial activity against E. coli by determine the OD values at 600 nm
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AMPs have broad spectrum antimicrobial activity 
in vitro, there are many obstacles in clinical application, 
such as cell toxicity, instability and high cost (Kim et al. 
2014). To solve these problems, many methods have been 
reported. For instance, substitution Trp and Phe residues 
with less hydrophobic amino acids can decreases the 
toxicity of AMPs (Kim et al. 2014). Introduction of non-
natural amino acids (mainly d-form amino acids), cycli-
zation or modification the terminal regions by acetylation 
or amidation can improve the stability of peptides (Wei 
and Bobek 2005; Kim et al. 2014).
In nature, almost all of the proteins and peptides were 
composed of l-amino acid. Different enzyme could rec-
ognize specific peptide bond formed by l-amino acid and 
break it (Chen et  al. 2016). However, enzyme could not 
break the peptide bond formed by d-amino acid for the 
difference of the spatial configuration. Actually, there is 
no difference between l-amino acid and its D-counter-
part in the chemical and physical property. So, d-amino 
acid substitution almost has no influence on the chemi-
cal and physical property of the peptides except the con-
figuration. As the influence of d-amino acid substitution 
on the biological activity of peptides, it is depend on 
that if the action mechanism related to the recognition 
of chiral targets (Braunstein et  al. 2004). In the present 
study, when only the three Lysines in the sequence of 
polybia-MPI were substituted by their D-counterparts, 
the secondary structure was changed compared to 
Fig. 6 The viability of bacteria/fungi after incubation with peptides in the presence/absence of enzyme. Each peptide was pre-incubated with dif-
ferent concentrations of chymotrypsin (a) or trypsin (b) at 37 °C for 4 h. Then the samples were heat inactivated and poured into wells of plates. The 
plates were incubated at 37 °C for 18–24 h. Controls were without trypsin or chymotrypsin
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polybia-MPI and the peptide almost lost all the biologi-
cal activity in the tested concentration. However, when 
all the l-amino acids in the sequence of polybia-MPI 
were substituted by d-amino acids, the configuration was 
reversed. The D-enantiomer of polybia-MPI was turned 
into left hand α-helical conformation. More importantly, 
all d-amino acid substitution didn’t affect its biological 
activity. D-MPI has the same antimicrobial activity even 
improved activity as polybia-MPI.
Furthermore, the action mechanism of D-MPI also 
was analyzed in the present study. The action mode of 
AMPs has been investigated in many studies. Many AMPs 
were found that they could bind with the membrane of 
microbes and then disrupt the integrity of cell membrane 
(Arnusch et al. 2012). There are mainly three models, the 
barrel-stave model, the toroidal pores model, and the car-
pet model (Chih et al. 2015), which are widely accepted to 
describe the membrane-active action mode. Membrane 
active action mode of AMPs was believed that it is difficult 
for microbes to develop resistance toward AMPs (Han-
cock and Sahl 2006). The L-counterpart of D-MPI mainly 
exerts its antitumor, antibacterial and antifungal activity 
through the disruption of the integrity of cell membrane 
(Wang et al. 2008, 2009, 2013, 2014). As expected, it may 
also exert its antimicrobial activity through disrupting the 
integrity of cell membrane and lead to the death of cells. 
This kind of cell membrane lysis action mechanism always 
was not dependent on the chiral recognition, which sup-
port that D-MPI retained the activity of its l-counterpart. 
Interestingly, all d-amino acid substitution also decreased 
the hemolytic activity of polybia-MPI.
In conclusion, our results showed that the fully sub-
stitution of all the amino acid of polybia-MPI with 
d-amino acid could protect the peptide from the degra-
dation of the tested proteases. This modification turned 
right hand α-helical conformation of polybia-MPI to left 
hand conformation and retained or improved the anti-
microbial activity of polybia-MPI. Although the par-
tially d-lysine substitution could improve the stability 
of polybia-MPI toward the tested protease, the second-
ary conformation was changed after modification and 
its antimicrobial activity decreased greatly. So, D-MPI 
Fig. 7 HPLC analysis of the susceptibility of polybia-MPI, D-MPI and D-lys-MPI to trypsin and chymotrypsin. Peptides at the concentration of 10 mM 
were incubated with trypsin or chymotrypsin at 37 °C. At the determined time interval, samples were taken and mixed with trifluoroacetic acid 
(TFA) and acetonitrile to precipitate proteins, respectively. Then the samples were detected with reverse phase high performance liquid chromatog-
raphy (RP-HPLC) analysis
Page 10 of 11Zhao et al. AMB Expr  (2016) 6:122 
may offer a new strategy and will be an excellent alter-
native to conventional antibiotics to defend the resistant 
bacteria.
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Fig. 8 Detection of peptides-induced PI uptake by LSCM. Mid-logarithmic-phase C. glabrata cells were incubated with 0 µM or 5× MIC peptides 
for 2 h. Then, PI (50 µg/ml) was added and was further incubated for 10 min in the dark. PI uptake was detected by LSCM. The control was done 
without peptide. Control (a–c); polybia-MPI (d–f); D-MPI (g–i). Bars, 50 µm
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